These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20599373)

  • 1. Is quantitative oestrogen receptor expression useful in the evaluation of the clinical prognosis? Analysis of a homogeneous series of 797 patients with prospective determination of the ER status using simultaneous EIA and IHC.
    Mazouni C; Bonnier P; Goubar A; Romain S; Martin PM
    Eur J Cancer; 2010 Oct; 46(15):2716-25. PubMed ID: 20599373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
    Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
    Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen.
    Khoshnoud MR; Löfdahl B; Fohlin H; Fornander T; Stål O; Skoog L; Bergh J; Nordenskjöld B
    Breast Cancer Res Treat; 2011 Apr; 126(2):421-30. PubMed ID: 20957430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
    Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
    Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
    JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy.
    Morgan DA; Refalo NA; Cheung KL
    Breast; 2011 Jun; 20(3):215-9. PubMed ID: 21159509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
    Dowsett M; Houghton J; Iden C; Salter J; Farndon J; A'Hern R; Sainsbury R; Baum M
    Ann Oncol; 2006 May; 17(5):818-26. PubMed ID: 16497822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
    Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.
    Azim HA; Kroman N; Paesmans M; Gelber S; Rotmensz N; Ameye L; De Mattos-Arruda L; Pistilli B; Pinto A; Jensen MB; Cordoba O; de Azambuja E; Goldhirsch A; Piccart MJ; Peccatori FA
    J Clin Oncol; 2013 Jan; 31(1):73-9. PubMed ID: 23169515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials.
    Alberts SR; Ingle JN; Roche PR; Cha SS; Wold LE; Farr GH; Krook JE; Wieand HS
    Cancer; 1996 Aug; 78(4):764-72. PubMed ID: 8756370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.
    Li Z; Tu Y; Wu Q; Wang Z; Li J; Zhang Y; Sun S
    Clin Breast Cancer; 2020 Apr; 20(2):e151-e163. PubMed ID: 31551181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer.
    Ettl J; Anders SI; Hapfelmeier A; Paepke S; Noske A; Weichert W; Klein E; Kiechle M
    Arch Gynecol Obstet; 2020 Dec; 302(6):1461-1467. PubMed ID: 32902674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.
    Nomura Y; Shirouzu M; Takayama T
    Breast Cancer Res Treat; 1998 May; 49(1):51-60. PubMed ID: 9694611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant radiation therapy alone is associated with improved overall survival compared to hormonal therapy alone in older women with estrogen receptor positive early stage breast cancer.
    Jhawar SR; Alpert N; Taioli E; Sayan M; Bazan J; Park KU; Stover D; Cherian M; White J; Haffty B; Ohri N
    Cancer Med; 2020 Nov; 9(22):8345-8354. PubMed ID: 32942344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
    Harvey JM; Clark GM; Osborne CK; Allred DC
    J Clin Oncol; 1999 May; 17(5):1474-81. PubMed ID: 10334533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis.
    L H Weischenfeldt K; Kirkegaard T; Rasmussen BB; Giobbie-Hurder A; Jensen MB; Ejlertsen B; Lykkesfeldt AE
    Acta Oncol; 2017 Sep; 56(9):1161-1167. PubMed ID: 28488912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.